TTY Biopharm Company Limited has announced its financial results for 2024, reporting a revenue of NT$5.893 billion and a pre-tax net profit of NT$1.885 billion. The company's net profit for the period reached NT$1.519 billion, with NT$1.449 billion attributable to the parent company. The basic earnings per share (EPS) stood at NT$5.83, marking a significant increase from NT$4.54 in 2023. In line with this strong performance, the board has proposed a dividend of NT$4.2 per share, up from NT$3.5 the previous year.

Growth Driven by U.S. and Southeast Asian Markets

TTY Biopharm anticipates single-digit percentage growth in revenue for 2025, driven by robust export demand from the United States and Southeast Asia. The company’s liposomal antibiotic, Lipo-AB, continues to see record-breaking shipments to the U.S. market. Additionally, TTY Biopharm is expanding its presence in Vietnam, with four products currently on the market and another four to five undergoing regulatory approval. Future plans include introducing antibiotics into the Vietnamese market as part of its regional expansion strategy.

Breakthrough in Locally Developed Antibiotics

In the domestic market, TTY Biopharm’s newly developed antibiotic, Polymyxin B, received National Health Insurance (NHI) reimbursement approval in December 2023. This marks a major milestone for TTY Biopharm as Polymyxin B is not only the company's first locally developed second-line antibiotic to be recognized by international treatment guidelines, but also Taiwan's first domestically produced second-line antibiotic with a new therapeutic indication. These achievements position TTY Biopharm as a key player in Taiwan’s antibiotic innovation landscape.

Resource: 東洋113年每股盈餘5.83元 擬配息4.2元